[
  {
    "ts": null,
    "headline": "Wells Fargo Notes Solid Q3 Results for CVS but Moderates 2025 Bull Case for HCB Segment",
    "summary": "CVS Health Corporation (NYSE:CVS) is included among the 15 Dividend Stocks that Outperform the S&P 500. On November 13⁠,​ Well‌s Fargo analyst Stephen Ba‌xter lowered‍ the firm’s pric⁠e target on CVS Health Corporation (NYSE:CVS) to⁠ $102 from⁠ $103 while maintaining an Overwe‍ight rating. The analyst‌ noted that Q3 results wer⁠e generally solid, t⁠hough the bul⁠lish […]",
    "url": "https://finnhub.io/api/news?id=5b32f81efeb6ab634a5a941cccfc5ca392fa565d5102a47f0b3365c9b3cf65e6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764792706,
      "headline": "Wells Fargo Notes Solid Q3 Results for CVS but Moderates 2025 Bull Case for HCB Segment",
      "id": 137678074,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CVS",
      "source": "Yahoo",
      "summary": "CVS Health Corporation (NYSE:CVS) is included among the 15 Dividend Stocks that Outperform the S&P 500. On November 13⁠,​ Well‌s Fargo analyst Stephen Ba‌xter lowered‍ the firm’s pric⁠e target on CVS Health Corporation (NYSE:CVS) to⁠ $102 from⁠ $103 while maintaining an Overwe‍ight rating. The analyst‌ noted that Q3 results wer⁠e generally solid, t⁠hough the bul⁠lish […]",
      "url": "https://finnhub.io/api/news?id=5b32f81efeb6ab634a5a941cccfc5ca392fa565d5102a47f0b3365c9b3cf65e6"
    }
  },
  {
    "ts": null,
    "headline": "CVS Health Corp. stock underperforms Wednesday when compared to competitors",
    "summary": "CVS Health Corp. stock underperforms Wednesday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=9197f1813b4d1a2d4b59c77c4813b380d2eab32f3a1c85d44a28303d7df85956",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764780000,
      "headline": "CVS Health Corp. stock underperforms Wednesday when compared to competitors",
      "id": 137685420,
      "image": "",
      "related": "CVS",
      "source": "MarketWatch",
      "summary": "CVS Health Corp. stock underperforms Wednesday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=9197f1813b4d1a2d4b59c77c4813b380d2eab32f3a1c85d44a28303d7df85956"
    }
  },
  {
    "ts": null,
    "headline": "CVS Health Still Long Crowded, Well-Liked Amid Investor Expectations for Upside, UBS Says",
    "summary": "CVS Health (CVS) is still \"long crowded and well-liked\" by investors ahead of next week's investor e",
    "url": "https://finnhub.io/api/news?id=04ca7aeb1a93acfce0734e579c19f51da08ffc37af2e9ccc005fdd6fa32a1079",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764779067,
      "headline": "CVS Health Still Long Crowded, Well-Liked Amid Investor Expectations for Upside, UBS Says",
      "id": 137672856,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CVS",
      "source": "Yahoo",
      "summary": "CVS Health (CVS) is still \"long crowded and well-liked\" by investors ahead of next week's investor e",
      "url": "https://finnhub.io/api/news?id=04ca7aeb1a93acfce0734e579c19f51da08ffc37af2e9ccc005fdd6fa32a1079"
    }
  },
  {
    "ts": null,
    "headline": "How CVS Elevating Vevye To Tier 1 Coverage At Harrow (HROW) Has Changed Its Investment Story",
    "summary": "Harrow, Inc. has secured a key win as CVS’s pharmacy benefit manager replaced Xiidra with Harrow’s dry eye drug Vevye on its Tier 1 formulary, and the company recently presented at BTIG Ophthalmology Day and the Piper Sandler Healthcare Conference in New York. This formulary upgrade at the largest U.S. PBM could materially improve patient access and prescription volumes for Vevye, reinforcing Harrow’s position in branded ophthalmic pharmaceuticals. We’ll now examine how CVS elevating Vevye...",
    "url": "https://finnhub.io/api/news?id=6b5e028157f00872ddcee0f218d49997984941f55cdb9469d841221c064a913e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764774691,
      "headline": "How CVS Elevating Vevye To Tier 1 Coverage At Harrow (HROW) Has Changed Its Investment Story",
      "id": 137671256,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CVS",
      "source": "Yahoo",
      "summary": "Harrow, Inc. has secured a key win as CVS’s pharmacy benefit manager replaced Xiidra with Harrow’s dry eye drug Vevye on its Tier 1 formulary, and the company recently presented at BTIG Ophthalmology Day and the Piper Sandler Healthcare Conference in New York. This formulary upgrade at the largest U.S. PBM could materially improve patient access and prescription volumes for Vevye, reinforcing Harrow’s position in branded ophthalmic pharmaceuticals. We’ll now examine how CVS elevating Vevye...",
      "url": "https://finnhub.io/api/news?id=6b5e028157f00872ddcee0f218d49997984941f55cdb9469d841221c064a913e"
    }
  },
  {
    "ts": null,
    "headline": "CVS Health Corporation (CVS) is Attracting Investor Attention: Here is What You Should Know",
    "summary": "Zacks.com users have recently been watching CVS Health (CVS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
    "url": "https://finnhub.io/api/news?id=e909fd894f83a53b059d184717d4511fa44dbf04ebc2e3309166ceb201a74954",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764770404,
      "headline": "CVS Health Corporation (CVS) is Attracting Investor Attention: Here is What You Should Know",
      "id": 137671258,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "CVS",
      "source": "Yahoo",
      "summary": "Zacks.com users have recently been watching CVS Health (CVS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.",
      "url": "https://finnhub.io/api/news?id=e909fd894f83a53b059d184717d4511fa44dbf04ebc2e3309166ceb201a74954"
    }
  }
]